The Right RIA For You. All content copyrighted © 2019 – onwards by Ambastha Financial LLC.
By Kuldip K. Ambastha On the trading day of Tuesday, November 1, 2022, Johnson & Johnson (JNJ), a major pharmaceutical and medical product provider, announced plans to acquire Abiomed, Inc. (ABMD), a medical device maker. Due to this development, for that day the stock price of Abiomed rose sharply by +49.9% per share, while the …
By Kuldip K. Ambastha The stock of BeiGene, Ltd. (BGNE), a commercial stage biopharmaceutical company focused on cancer treatment drugs, saw a +20.5% increase in price per share on Wednesday, October 12, 2022. Brukinsa (zanubrutinib) in its Phase 3 trial data showed highly positive results in people with chronic lymphocytic leukemia (CLL) or small lymphocytic …
Continue reading “What Caught Our Attention in the Investment World? – Week of October 10-14, 2022”
By Kuldip K. Ambastha The stock of Regeneron Pharmaceuticals, Inc. (REGN), a biotechnology company with a portfolio of medicines for individuals with serious diseases, increased in price by +18.8% per share on the trading day of Thursday, September 8, 2022. Eylea (aka: aflibercept), an anti-blindness eye medication, was the cause of this price run-up, because …
Continue reading “What Caught Our Attention in the Investment World? – Week of September 6-9, 2022”
By Kuldip K. Ambastha On Wednesday, July 27, 2022, the stock of global pharmaceutical company Teva Pharmaceutical Industries Limited (TEVA) rose in price by +28.4% per share. Teva is the world’s largest generic medicine producer, and has been struggling for the last five years because of weakness in the American generic medicine sector plus intense …
Continue reading “What Caught Our Attention in the Investment World? – Week of July 25-29, 2022”
By Kuldip K. Ambastha On Friday, September 3, 2021, the stock of Forte Biosciences, Inc. (FBRX) stood out for its substantial trading day loss of -82.3%. Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on potential treatments for inflammatory skin diseases. The company released results of a Phase 2 clinical trial of FB-401, related …
By Kuldip K. Ambastha Sonoma Pharmaceuticals Inc. (SNOA) is a specialty pharmaceutical company focused on conditions which could be treated using stabilized hypochlorous acid (HOCl or HClO) in various ways. The company’s stock had a volatile end for this past trading week, with a gain of +50.6% on Thursday, August 19, 2021 followed by a …
Continue reading “What Caught Our Attention in the Investment World? – Week of August 16-20, 2021”
By Kuldip K. Ambastha Until recently, Eastman Kodak Company (KODK) had been best known for its famous camera and photography offerings from the past. The company was founded in 1888, in Rochester, New York. With the rise of new technology offerings such as sophisticated smartphone cameras, Eastman Kodak Company was not in the press as …
Continue reading “What Caught Our Attention in the Investment World? – Week of July 27 – 31, 2020”
By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …
Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”
By Kuldip K. Ambastha and Anil K. Ambastha On Thursday, December 5, 2019, there was “a tale of two cities,” to quote Charles Dickens. In the biotech arena, SAGE (Sage Therapeutics, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) were big movers. Sage Therapeutics delivered -59.7% for the day, while Aurinia Pharmaceuticals returned 78.8%. SAGE-217 is a …
Continue reading “What Caught Our Attention in the Investment World? – Week of December 2-6, 2019”
By Kuldip K. Ambastha and Anil K. Ambastha Karuna Therapeutics Inc. (KRTX), a clinical-stage biopharmaceutical company, was founded in 2009 and is headquartered in Boston, MA. The company is focused on developing innovative therapies for individuals suffering from disabilities, disorders, and pain. Karuna Therapeutics Inc. has announced that its schizophrenia treatment’s Phase 2 clinical trial …
Continue reading “What Caught Our Attention in the Investment World? – Week of November 18-22, 2019”